NKTR-192 / Nektar Therapeutics - LARVOL DELTA

Nektar doses first subjects in phase 1 clinical study evaluating NKTR-192, a new short-acting opioid molecule for the treatment of acute pain (PRNewswire) - Nektar Therapeutics announced that the first subjects were dosed last week in a P1 clinical study to evaluate the pharmacokinetics and safety of NKTR-19, the company's novel short-acting mu-opioid analgesic candidate; Nektar plans to advance NKTR-181 into P2 clinical development in chronic pain patients in mid-2012

Anticipated P2 trial • P1 update • Pain

NKTR-192, a new short-acting mu-opioid analgesic molecule, achieves desired pharmacokinetic profile in first phase 1a clinical study (PRNewswire) - P1, N=48; "Dosing has commenced in a second single-ascending dose Phase 1a clinical study of NKTR-192; Results from our first clinical study of NKTR-192 demonstrated that this new mu-opioid molecule achieved a short-acting pharmacokinetic profile which is ideal for the treatment of acute pain"

New P1 trial • P1 data • Pain